免疫检查点抑制剂（ICIs）联合化疗已成为多种晚期恶性肿瘤的标准一线治疗方案，能带来显著的生存获益，但化疗的骨髓抑制风险却像悬在头顶的“达摩克利斯之剑”——一旦发生严重的中性粒细胞减少或FN，不仅可能导致治疗中断，还可能引发危及生命的感染。

德国血液学和肿瘤学会感染性疾病工作组（AGIHO）更新了2014年版指南，针对粒细胞集落刺激因子（G-CSF）在成人癌症患者感染并发症预防中的应用提出循证建议。该指南通过系统文献回顾（2014-2024年）和专家共识会议，明确了G-CSF在实体瘤、血液肿瘤及新兴免疫 ...

The choice of whether to use granulocyte colony-stimulating factor (G-CSF) for the prevention of febrile neutropenia for patients undergoing chemotherapy depends on whether it is being used for ...

The optimization of 5-fluorouracil (5FU) dose by pharmacokinetic (PK) monitoring in Asian patients with advanced-stage gastrointestinal (GI) cancer. This is an ASCO Meeting Abstract from the 2015 ...

Five hundred and six stage I or stage II female breast cancer patients were treated with E 120 mg/m 2 and C 600 mg/m 2 with or without G-CSF and randomly assigned to receive in a factorial 2 × 2 ...